Ipsen S.A. (0MH6.IL)

112.30 -0.50 (-0.44%) At close: 06:06PM BST

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 5,300

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David Loew	MD, CEO & Director	2.22M	N/A	1967
Mr. Aymeric Le Chatelier	Exec. VP & Group CFO	N/A	N/A	1969
Dr. Aidan Murphy Ph.D.	Exec. VP of Technical Operations	N/A	N/A	1966
Mr. Craig Marks	Vice-Pres of Investor Relations	N/A	N/A	N/A
Mr. Francois Garnier	Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer	N/A	N/A	1962
Ms. Gwenan White	Exec. VP of Communications, Public Affairs & Sustainability	N/A	N/A	N/A
Mr. Regis Mulot	Exec. VP & Chief HR Officer	N/A	N/A	1966
Ms. Dominique Bery	Head of Nordics & Baltics	N/A	N/A	1971
Dr. Yan Moore M.D.	Sr. VP & Head of Oncology Therapeutic Area	N/A	N/A	1967
Dr. Alexander McEwan	Vice-Pres & Head of Radiopharmaceuticals	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Corporate governance

Ipsen S.A.’s ISS governance QualityScore as of 1 October 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.